399% increase in the price of two drugs of the subsidiary company, and the response of humanwell to the price adjustment

Recently, a media report on the rise of drug prices by American pharmaceutical companies mentioned that epic Pharma "raised the prices of two drugs by 399%" On July 11, humanwell pharmaceutical made a statement on the adjustment of drug prices by epic Pharma, a wholly-owned subsidiary of the company Epic Pharma recently increased the prices of three products The price increase is only a market-based adjustment based on the operating costs of the enterprise and the market supply and demand of the products Epicpharma company is a U.S generic pharmaceutical enterprise integrating R & D, production and sales At present, it produces and operates more than 200 chemical generic drugs, including ursodeoxycholic acid capsules, potassium chloride powder, azithromycin dry suspension, oxycodone hydrochloride tablets, sulindac tablets, chlorphenazine hydrochloride tablets, nicardipine hydrochloride tablets, etc According to humanwell, epicpharma has recently raised the prices of three products The price increase is only a market-oriented adjustment based on the operating costs of the enterprise and the market supply and demand of the products The escalation of E picpharma's products is not completely consistent with the reported content As the detailed information involves the company's trade secrets, it cannot be disclosed here The above three products do not involve epicpharma's core product ursodeoxycholic acid capsule In 2018, the total sales revenue of the above three products is about 3 million US dollars, accounting for about 4% of epicpharma's business revenue in 2018.